Differentiation of Adipose-Derived Stem Cells into Smooth Muscle Cells in an Internal Anal Sphincter-Targeting Anal Incontinence Rat Model.
Kim M., Oh BY., Lee JS., Yoon D., Kim YR., Chun W.
Animal Study with a reported sample of 10, published in J Clin Med (2023) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- J Clin Med (2023)
- Country
- Switzerland
- Reported sample size
- 10
- Source database
- PubMed
- PMID
- 36836167
- PMCID
- PMC9959483
- DOI
- 10.3390/jcm12041632
- Citations
- 2
Abstract (original English)
Abstract Background: Studies on the development of a faecal incontinence (FI) model targeting smooth muscle cells (SMCs) of the internal anal sphincter (IAS) have not been reported. Differentiation of implanted human adipose-derived stem cells (hADScs) into corresponding SMCs in an IAS-targeting FI model has also not been demonstrated. We aimed to develop an IAS-targeting FI animal model and to determine the differentiation of hADScs into SMCs in the established IAS-targeting animal model. Methods: An IAS-targeting FI model was developed by inducing cryoinjury at the inner side of the muscular layer via posterior intersphincteric dissection in Sprague–Dawley rats. After in vitro confirmation of differentiation ability into SMCs, implantation of Dil-stained hADScs (1×10 6 cells per site) was immediately performed at the IAS injury site via microscopic needling. Multiple markers, including α-smooth muscle actin (α-SMA), SM22α, calponin, caldesmon, smooth muscle myosin heavy chain (SMMHC), smoothelin, stromal cell-derived factor 1 (SDF-1), monocyte chemoattractant protein 3 (MCP-3), fibronectin, CoL1A1, and transforming growth factor β (TGF- β ), were used to confirm molecular changes in smooth muscles before implantation (n = 10) and after differentiation of labelled cells at one and two weeks after implantation (n = 20). These analyses were performed using H&E staining, immunofl
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.